Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Research Article
  • Published:

Growth hormone treatment in pre-pubertal short Chinese children with chronic kidney disease prior to transplantation

Abstract

Background

The effect of recombinant human GH (rhGH) in Chinese children with chronic kidney disease (CKD) is unclear.

Methods

This was a 52-week, multicenter, randomized, open-label, negative-controlled phase 3 study. Prepubertal subjects were randomized 1:1 to either daily subcutaneous injections of rhGH 0.05 mg/kg/day or no treatment for 52 weeks.

Results

A total of 68 subjects with a mean age of 7.8 ± 3.27 years were enrolled. At week 52, the height standard deviation score (HT-SDS) in the treated group increased by 0.75 ± 0.58, which was significantly higher compared with 0.17 ± 0.47 in the untreated group (least squares mean 0.58, 95% confidence interval, 0.32–0.84; P < 0.001). At week 52, significant improvements were observed in other growth parameters (height velocity [P < 0.001]), insulin-like growth factor 1 (IGF-1) SDS [P < 0.001], IFG-1/insulin-like growth factor binding protein-3 molar ratio [P < 0.001], and height [P < 0.001]) compared with the untreated control. Seven patients reported treatment-related adverse events (TRAEs) and most TRAEs were mild in severity. Most subjects recovered without further intervention.

Conclusions

Daily rhGH for 52 weeks in children with CKD-induced growth retardation significantly improved HT-SDS and other growth parameters without compromising safety.

Impact

  • The efficacy and safety of growth hormone (GH) therapy in Chinese children with chronic kidney disease (CKD) are unclear.

  • This study found that giving short stature Chinese children with CKD daily recombinant human growth hormone (rhGH) for 52 weeks improved growth parameters without compromising safety.

  • This study’s information can give physicians the confidence to treat these patients in their clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Patient disposition.
Fig. 2: Effect of treatment on growth parameters.

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are not publicly available due individual privacy of clinical trial participants should be protected but are available from the corresponding author on reasonable request.

References

  1. Janjua, H. S. & Mahan, J. D. Growth in chronic kidney disease. Adv. Chronic Kidney Dis. 18, 324–331 (2011).

    Article  PubMed  Google Scholar 

  2. Mahan, J. D. et al. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr. Nephrol. 21, 917–930 (2006).

    Article  PubMed  Google Scholar 

  3. Tonshoff, B., Kiepe, D. & Ciarmatori, S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr. Nephrol. 20, 279–289 (2005).

    Article  PubMed  Google Scholar 

  4. Roelfsema, V. & Clark, R. G. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. J. Am. Soc. Nephrol. 12, 1297–306. (2001).

    Article  CAS  PubMed  Google Scholar 

  5. Drube, J. et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat. Rev. Nephrol. 15, 577–89. (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fine, R. N., Attie, K. M., Kuntze, J., Brown, D. F. & Kohaut, E. C. Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Genentech Collaborative Study Group. Pediatr. Nephrol. 9, 451–457 (1995).

    Article  CAS  PubMed  Google Scholar 

  7. Fine, R. N., Kohaut, E., Brown, D., Kuntze, J. & Attie, K. M. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int. 49, 781–785 (1996).

    Article  CAS  PubMed  Google Scholar 

  8. Fine, R. N., Kohaut, E. C., Brown, D. & Perlman, A. J. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J. Pediatr. 124, 374–382 (1994).

    Article  CAS  PubMed  Google Scholar 

  9. Pozzo, A. M. & Kemp, S. F. Growth and growth hormone treatment in children with chronic diseases. Endocrinol. Metab. Clin. North Am. 41, 747–759 (2012).

    Article  PubMed  Google Scholar 

  10. Group, K. W. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am. J. Kidney Dis. 53, S11–S104 (2009).

    Article  Google Scholar 

  11. Li, H., Ji, C. Y., Zong, X. N. & Zhang, Y. Q. [Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years]. Zhonghua Er Ke Za Zhi 47, 487–492 (2009).

    PubMed  Google Scholar 

  12. Hodson, E. M., Willis, N. S. & Craig, J. C. Growth hormone for children with chronic kidney disease. Cochrane Database Syst. Rev. 2012, CD003264 (2012).

  13. Hertel, N. T. et al. Recombinant human growth hormone treatment, using two dose regimens in children with chronic renal failure-a report on linear growth and adverse effects. J. Pediatr. Endocrinol. Metab. 15, 577–588 (2002).

    Article  CAS  PubMed  Google Scholar 

  14. Kuizon, B. D. & Salusky, I. B. Growth retardation in children with chronic renal failure. J. Bone Min. Res 14, 1680–1690 (1999).

    Article  CAS  Google Scholar 

  15. Kitagawa, T. et al. GH treatment of children with chronic renal insufficiency: a Japanese clinical trial. Clin. Pediatr. Endocrinol. 6, 73–80 (1997).

    Article  Google Scholar 

  16. Haffner, D. et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N. Engl. J. Med 343, 923–930 (2000).

    Article  CAS  PubMed  Google Scholar 

  17. Hokken-Koelega, A. et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr. Nephrol. 14, 701–706 (2000).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We sincerely thank the patients who participated in this study and their families and all personnel at each study site who cared for the patients and coordinated with the sponsor to make this trial possible. We thank Feihong Luo and Ruoqian Cheng of Children’s Hospital of Fudan University for Tanner stage assessment, and Ping Yin of Huazhong University of Science and Technology for assisting the statistical work. We thank Mengmeng Chen of GeneScience Pharmaceuticals for editorial assistance; Lawrence Law of Parexel for medical writing support.

Funding

This research was funded by GeneScience Pharmaceuticals. The funder was involved in the design and conduct of the study; collection, management, analysis; review of the manuscript; and decision to submit the manuscript for publication.

Author information

Authors and Affiliations

Authors

Contributions

All authors meet all four of the International Committee of Medical Journal Editors’ (ICMJE) criteria for authorship: • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; • Drafting the work or revising it critically for important intellectual content; • Final approval of the version to be published; • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. X.T., Q.C. drafted the initial manuscript, carried out the initial analyses and and revised the manuscript. H.X., X.L., W.H., C.C., Y.W., J.M., X.N., C.L., Y.L., J.Z., M.W. revised the manuscript for important intellectual content. Z.Y., J.C., X.F., F.Z., P.W., L.S., K.X., Z.C., J.T., X.W., Z.L., J.W., J.H., G.C., Y.Z., H.Y. offered administrative, technical, or material support. A.Z., M.W. obtained the study funding. Q.S. and H.X. conceptualized and designed the study, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Corresponding authors

Correspondence to Qian Shen or Hong Xu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Consent to participate

Written informed consent was obtained prior to the patient entering the study. The investigators explained the nature, purpose, and risks of the study to each patient/guardian. Each patient/guardian was informed that he/she could withdraw from the study at any time and for any reason. Each patient/guardian was given sufficient time to consider the implications of the study before deciding whether to participate. Patients/guardians who chose to participate signed an informed consent document.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, X., Chen, Q., Chen, J. et al. Growth hormone treatment in pre-pubertal short Chinese children with chronic kidney disease prior to transplantation. Pediatr Res 94, 268–274 (2023). https://doi.org/10.1038/s41390-022-02429-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41390-022-02429-6

Search

Quick links